Related Experiment Video
Updated: Jul 5, 2025
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Identifying novel inhibitors targeting Exportin-1 for the potential treatment of COVID-19
Tanuj Sharma1, Tanmoy Mondal2,3, Sajid Khan4
1Department of Family Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Gangnam-gu, Seoul, 06273, Republic of Korea.
Abstract:
The nuclear export protein 1 (XPO1) mediates the nucleocytoplasmic transport of proteins and ribonucleic acids (RNAs) and plays a prominent role in maintaining cellular homeostasis. XPO1 has emerged as a promising therapeutic approach to interfere with the lifecycle of many viruses. In our earlier study, we proved the inhibition of XPO1 as a therapeutic strategy for managing SARS-COV-2 and its variants. In this study, we have utilized pharmacophore-assisted computational methods to identify prominent XPO1 inhibitors. After several layers of screening, a few molecules were shortlisted for further experimental validation on the in vitro SARS-CoV-2 cell infection model. It was observed that these compounds reduced spike positivity, suggesting inhibition of SARS-COV-2 infection. The outcome of this study could be considered further for developing novel antiviral therapeutic strategies against SARS-CoV-2.
Insights
Researchers identified novel inhibitors of nuclear export protein 1 (XPO1) using computational methods. These compounds showed promise in reducing SARS-CoV-2 infection in laboratory tests, suggesting potential new antiviral therapies.
Area of Science:
- Molecular Biology
- Virology
- Drug Discovery
Background:
- Nuclear export protein 1 (XPO1) regulates nucleocytoplasmic transport, crucial for cellular homeostasis.
- XPO1 is a potential therapeutic target for viral infections, including SARS-CoV-2.
Purpose of the Study:
- To identify novel XPO1 inhibitors using pharmacophore-assisted computational methods.
- To validate the efficacy of identified inhibitors against SARS-CoV-2 infection in vitro.
Main Methods:
- Pharmacophore-assisted computational screening to identify XPO1 inhibitors.
- In vitro experimental validation using a SARS-CoV-2 cell infection model.
- Assessment of viral spike protein expression to evaluate infection inhibition.
Main Results:
- Computational methods successfully identified potential XPO1 inhibitors.
- Shortlisted compounds demonstrated reduced SARS-CoV-2 spike positivity in vitro.
- These findings suggest XPO1 inhibition effectively combats SARS-CoV-2 infection.
Conclusions:
- The study validates XPO1 as a viable therapeutic target for SARS-CoV-2.
- Identified compounds represent promising candidates for novel antiviral drug development.
- Further research can advance these findings into clinical applications against SARS-CoV-2.
More Related Videos
05:36Author Spotlight: Development of a Large-Scale, Reproducible Production Method for Exosome Mimetics Using Magnetic Nanoparticles
Published on: January 26, 2024
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
